News headlines about Teva Pharmaceutical Industries (NYSE:TEVA) have trended somewhat positive recently, Accern reports. The research group identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Teva Pharmaceutical Industries earned a daily sentiment score of 0.09 on Accern’s scale. Accern also gave news coverage about the company an impact score of 44.9626048353246 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the news articles that may have impacted Accern’s rankings:
- Wells Fargo & Co Reiterates Sell Rating for Teva Pharmaceutical Industries (TEVA) (americanbankingnews.com)
- Teva Pharmaceutical Industries’ (TEVA) “Hold” Rating Reiterated at Maxim Group (americanbankingnews.com)
- Teva Late-stage Trial Of Asthma Treatment Fails To Meet Primary Endpoint (nasdaq.com)
- Teva Pharmaceutical Industries Ltd (ADR): New Restructuring Initiative Is Solid Move- Now Let’s “See How It Plays Out,” Says Jason Kolbert (smarteranalyst.com)
- Teva shares decline on negative late-stage trial results for asthma therapy (finance.yahoo.com)
Teva Pharmaceutical Industries (NYSE TEVA) traded up $0.32 during trading on Monday, reaching $21.02. 20,758,579 shares of the company were exchanged, compared to its average volume of 27,110,000. Teva Pharmaceutical Industries has a fifty-two week low of $10.85 and a fifty-two week high of $37.94. The stock has a market cap of $20,960.00, a price-to-earnings ratio of -3.58, a price-to-earnings-growth ratio of 1.48 and a beta of 0.54. The company has a debt-to-equity ratio of 1.20, a current ratio of 0.96 and a quick ratio of 0.66.
Several equities analysts have commented on TEVA shares. ValuEngine raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Tuesday, December 5th. Evercore ISI set a $38.00 target price on shares of Teva Pharmaceutical Industries and gave the stock a “buy” rating in a research report on Wednesday, October 25th. Cantor Fitzgerald set a $17.00 target price on shares of Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research report on Thursday, October 26th. Morgan Stanley set a $15.00 target price on shares of Teva Pharmaceutical Industries and gave the stock an “underweight” rating in a research report on Thursday, October 5th. Finally, Mizuho reaffirmed a “hold” rating and issued a $15.00 price target on shares of Teva Pharmaceutical Industries in a report on Monday, October 30th. Eight investment analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $21.32.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.